We are live on ! Find out more
GWPH

GW Pharmaceuticals Plc American Depositary Shares
GWPH

Delisted

GWPH was delisted on the 4th of May, 2021.

277 hedge funds and large institutions have $2.28B invested in GW Pharmaceuticals Plc American Depositary Shares in 2018 Q4 according to their latest regulatory filings, with 74 funds opening new positions, 79 increasing their positions, 71 reducing their positions, and 67 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

11% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 71

10% more first-time investments, than exits

New positions opened: 74 | Existing positions closed: 67

2% more funds holding

Funds holding: 272277 (+5)

9% more call options, than puts

Call options by funds: $101M | Put options by funds: $92.9M

35% less capital invested

Capital invested by funds: $3.54B → $2.28B (-$1.25B)

Holders
277
Holders Change
+5
Holders Change %
+1.84%
% of All Funds
6.17%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.09%
New
74
Increased
79
Reduced
71
Closed
67
Calls
$101M
Puts
$92.9M
Net Calls
+$8.04M
Net Calls Change
+$69M
Name Holding Trade Value Shares
Change
Change in
Stake
MA
301
MYDA Advisors
New York
-$210K -1,600 Closed
PA
302
Pinnacle Associates
New York
-$263K -1,525 Closed
Mariner
303
Mariner
Kansas
-$250K -1,446 Closed
BTS
304
BB&T Securities
Virginia
-$249K -1,445 Closed
11A
305
10-15 Associates
New York
-$249K -1,440 Closed
BS
306
Boenning & Scattergood
Pennsylvania
-$242K -1,400 Closed
CA
307
Continuum Advisory
Idaho
-$234K -1,400 Closed
SGCA
308
Steel Grove Capital Advisors
Tennessee
-$220K -1,271 Closed
FA
309
FDx Advisors
Illinois
-$216K -1,253 Closed
HM
310
Harvest Management
New York
-$207K -1,200 Closed
CIM
311
Confluence Investment Management
Missouri
-$206K -1,195 Closed
OC
312
Oppenheimer & Co
New York
-$205K -1,185 Closed
SFS
313
Sowell Financial Services
Arkansas
-$204K -1,179 Closed
SPIA
314
Steward Partners Investment Advisory
New York
-$126K -731 Closed
HCM
315
Highlander Capital Management
New Jersey
-$86K -500 Closed
KF
316
Krilogy Financial
Missouri
-$82K -475 Closed
OIA
317
Optimum Investment Advisors
Illinois
-$52K -300 Closed
WSTAM
318
Wilbanks Smith & Thomas Asset Management
Virginia
-$48K -277 Closed
SCM
319
Southport Capital Management
Tennessee
-$42K -245 Closed
CWM
320
Catamount Wealth Management
Connecticut
-$35K -200 Closed
JWA
321
JFS Wealth Advisors
Pennsylvania
-$35K -200 Closed
MYIA
322
Mount Yale Investment Advisors
Colorado
-$27K -181 Closed
GP
323
Girard Partners
Pennsylvania
-$30K -175 Closed
APP
324
Avantax Planning Partners
Iowa
-$22K -126 Closed
IGGA
325
Iron Gate Global Advisors
Utah
-$16K -126 Closed

GWPH Hedge Fund Activity: Q4 2018 in Review

277 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q4 2018, worth a combined $2.28B — down 35% from $3.54B a quarter earlier.

Buyers outnumbered sellers: 74 funds opened new GWPH positions and 67 closed out — a net gain of 7 holders — while 79 added to existing stakes and 71 trimmed.

The largest buyer was Canada Pension Plan Investment Board, adding an estimated $118M. The largest seller was Citadel Advisors, cutting an estimated $57M.

  • 277 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q4 2018, up from 272 in Q3 2018.
  • Funds reported $2.28B of GW Pharmaceuticals Plc American Depositary Shares stock for Q4 2018, down 35% quarter-over-quarter.
  • 74 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q4 2018 and 67 closed out, a net change of +7 holders.
  • The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q4 2018 was Canada Pension Plan Investment Board, an estimated $118M added.
  • The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q4 2018 was Citadel Advisors, an estimated $57M sold.

Based on aggregated 13F filings for Q4 2018.